Lumpectomy for mammary carcinoma. A retrospective analysis of 40 presumptive candidates from a surgical series

Pickren, John W.; Satchidanand, Yashodhara; Lane, Warren W.; Haagensen, C. D.

doi:10.1002/1097-0142(19841015)54:8<1692::aid-cncr2820540834>3.0.co;2-4

Cancer

1984

DOI: 10.1002/1097-0142(19841015)54:8<1692::aid-cncr2820540834>3.0.co;2-4

|View full text |Cite

Lumpectomy for mammary carcinoma. A retrospective analysis of 40 presumptive candidates from a surgical series

John W. Pickren¹,

Yashodhara Satchidanand²,

Warren W. Lane

et al.

Abstract: This presumptive study concerns the value of lumpectomy as a curative procedure for minimal breast carcinoma, defined as an operable cancer no larger than 2 cm in diameter, with no palpable axillary lymph nodes, and, in peripherally located lesions, no Paget's disease. From 199 surgically treated mammary cancer patients, 40 cases met the minimal criteria. Thirty‐eight of the minimal breast carcinoma patients had a radical mastectomy and two had a supraradical procedure. The pathology findings and survival data… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1992

2008

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Radiation therapy for operable breast cancer

Freedman

2008

Cancer

View full text Add to dashboard Cite

This review examined the 60 years of progress made in treating breast cancer from the unique perspective of the reader of Cancer, with a specific emphasis on the evolution of radiation therapy, constituting a survey of the published articles in each decade, and the standards of treatment and controversies of their times that they portray, in 3 major areas: radiation as an adjuvant therapy to mastectomy, radiation for internal mammary lymph node treatment, and radiation with breast-conserving surgery as an alternative to mastectomy. Cancer 2008;113(7 suppl):1779-800.

show abstract

Radiation therapy for operable breast cancer

Freedman

2008

Cancer

View full text Add to dashboard Cite

show abstract

The Evolution of Accelerated, Partial Breast Irradiation as a Potential Treatment Option for Women with Newly Diagnosed Breast Cancer Considering Breast Conservation

Dirbas

Jeffrey²,

Goffinet³

2004

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Breast conservation therapy (BCT) is a safe, effective alternative to mastectomy for many women with newly diagnosed breast cancer. This approach involves local excision of the malignancy with tumor-free margins, followed by 5-7 weeks of external beam whole breast (WB) radiotherapy (XRT) to minimize the risk of an in-breast tumor recurrence (IBTR). Though clearly beneficial, the extended course of almost daily postoperative radiotherapy interrupts normal activities and lengthens care. Additional options are now available that shorten the radiotherapy treatment time to 1-5 days (accelerated) and focus an increased dose of radiation on just the breast tissue around the excision cavity (partial breast). Recent trials with accelerated, partial breast irradiation (APBI) have shown promise as a potential replacement to the longer, whole breast treatments for select women with early-stage breast cancer. Current APBI approaches include interstitial brachytherapy, intracavitary (balloon) brachytherapy, and accelerated external beam (3-D conformal) radiotherapy, all of which normally complete treatment over 5 days, while intraoperative radiotherapy (IORT) condenses the entire treatment into a single dose delivered immediately after tumor excision. Each approach has benefits and limitations. This study covers over 2 decades of clinical trials exploring APBI, discusses treatment variables that appear necessary for successful implementation of this new form of radiotherapy, compares and contrasts the various APBI approaches, and summarizes current and planned randomized trials that will shape if and how APBI is introduced into routine clinical care. Some of the more important outcome variables from these trials will be local toxicity, local and regional recurrence, and overall survival. If APBI options are ultimately demonstrated to be as safe and effective as current whole breast radiotherapy approaches, breast conservation may become an even more appealing choice, and the overall impact of treatment may be further reduced for certain women with newly diagnosed breast cancer.

show abstract

Breast-conserving Therapy for Mammary Carcinoma Psychosocial Aspects, Indications and Limitations

Blichert-Toft

1992

Annals of Medicine

View full text Add to dashboard Cite

Breast-conserving therapy (BCT) for invasive cancer comprises complete tumour excision and axillary dissection, followed by irradiation. The object is to perform local treatment and determine the stage of disease on lines similar to those of mastectomy. In selected series of patients the efficacy of BCT has been equivalent to that of mastectomy with a view to distant relapse and survival. On the other hand, it has not been proved whether local relapse pattern is comparable to that of mastectomy, especially in high-risk patients. The advantage of BCT is of psychological nature, since preserving the configuration of the body maintains the sensation of female identity and body image to a better extent than that seen after mastectomy. BCT does not, however, reduce the high frequency of anxiety phenomena, mental instability, and depression. The selection of patients for BCT is based primarily upon a clinical-technical assessment, patient's preference and surgeon's preference, rather than eligibility based on biological risk factors. Demands on surgical technique, radicality of operation, and irradiation are important issues regarding local control. The relation between local recurrence rate and distant relapse will be discussed. The conclusion is that BCT is a method eligible for selected patients and that the increased used of mammography is going to extend the intake of patients for the method. However, it must be an obligation to keep following up the therapeutic results, in order not to lose the advantage of an early diagnosis by altered treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Lumpectomy for mammary carcinoma. A retrospective analysis of 40 presumptive candidates from a surgical series

Cited by 3 publications

References 9 publications

Radiation therapy for operable breast cancer

Radiation therapy for operable breast cancer

The Evolution of Accelerated, Partial Breast Irradiation as a Potential Treatment Option for Women with Newly Diagnosed Breast Cancer Considering Breast Conservation

Breast-conserving Therapy for Mammary Carcinoma Psychosocial Aspects, Indications and Limitations

Contact Info

Product

Resources

About